May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Triple Therapy for the Treatment of Wet Amd
Author Affiliations & Notes
  • A. J. Augustin
    Ophthalmology, Sulzfeld, Sulzfeld, Germany
  • S. Puls
    Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany
  • I. Offermann
    Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany
  • Footnotes
    Commercial Relationships A.J. Augustin, QLT, R; S. Puls, None; I. Offermann, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1829. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. J. Augustin, S. Puls, I. Offermann; Triple Therapy for the Treatment of Wet Amd. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1829. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy and safety of triple therapy with verteporfin PDT (PDT), dexamethasone, and bevacizumab in CNV secondary to AMD.

Methods:: This prospective, noncomparative, interventional case series included 104 patients. PDT was administered with a reduced light dose (42 J/cm2, accomplished by light delivery time of 70 seconds). About 16 hours after PDT, dexamethasone (800 µg) and bevacizumab (1.5 mg) were injected intravitreally. Patients attended follow-up visits every 6 weeks, undergoing VA and intraocular pressure measurement, slit-lamp and ophthalmoscopic examination, and optical coherence tomography. Fluorescein angiography was performed every 3 months or earlier if OCT showed significant edema.

Results:: All 104 patients received one triple therapy cycle (5 patients received a second triple treatment due to remaining CNV activity). The triple therapy was complemented in 18 patients (17,3%) by an additional intravitreal injection of bevacizumab. The mean follow-up period was 40 weeks (range, 22-60 weeks). Mean increase in visual acuity was 1.8 lines (P<0.01). Mean decrease in retinal thickness was 182 µm (P<0.01). No serious adverse events have been observed.

Conclusions:: In most of the patients with CNV due to AMD, triple therapy results in significant and sustained visual acuity improvement after only one cycle of treatment. In addition, the therapy offers a good safety profile, potentially lower cost compared with therapies that must be administered more frequently and convenience for patients. Extended follow up will be presented.

Keywords: choroid: neovascularization • age-related macular degeneration • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×